Presentation to the American Society of Hematology (ASH) 2017 Annual Meeting Coincides with Publication of Catalent Biologics’ Research Manuscript
Toronto, Ontario, and Somerset, N.J. - December 4, 2017 – Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced Triphase’s upcoming ASH presentation as well as Catalent’s key publication relating to the preclinical development of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.
Triphase announced that its preclinical abstract describing TRPH-222, has been accepted by the American Society of Hematology as a poster presentation at the 59th ASH Annual Meeting & Exposition, taking place from December 9-12, 2017 at the Georgia World Congress Center, Atlanta, Georgia. The poster, by MacLaren, et. al., titled “TRPH-222, a Novel Anti-CD22 Antibody Drug Conjugate, Has Significant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates,” will be presented in session 625 on Monday, December 11, 2017 from 6:00 p.m. to 8:00 p.m., in building A, level 1, hall A2.
Also today, Catalent Biologics announced the publication of a manuscript by Drake, et. al., titled, “CAT-02-106, a site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical models,” in Molecular Cancer Therapeutics, a high impact, peer-reviewed medical journal describing preclinical data from novel therapeutic agents. CAT-02-106 was Catalent’s research designation for the TRPH-222 program prior to Triphase acquiring the worldwide rights to further develop the program from Catalent Biologics in 2016. CAT-02-106 was developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, using its proprietary SMARTag® platform.
“We continue to be encouraged by the pre-clinical data from the TRPH-222 program, indicating better tolerability and an expanded therapeutic index for this SMARTag ADC compared to conventional ADCs,” commented Dr. Henry Lowman, Executive Director of Research and Development at Triphase. “We believe this molecule can play an important role in the treatment of lymphoma and we are committed to accelerating its development into the clinic.”
“We are excited about the rapid progress Triphase has achieved with this important compound, and pleased to be partnering with such a capable organization to advance this treatment to patients,” added Mike Riley, Vice President & General Manager of Catalent Biologics.
+44 (0)7580 041073
+44 (0) 161 728 5880
TRPH-222 is a novel, site-specific antibody-drug conjugate (ADC) targeting CD22, a B-cell-restricted sialo-glycoprotein that is an important modulator of B-cell signaling and survival, and is expressed on nearly all B-cell malignancies. CD22 is a clinically validated ADC target with potential in Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The compound itself combines a site-specific modified humanized antibody conjugated to a cytotoxic payload using Hydrazino-Pictet-Spengler (HIPSTM) chemistry and a proprietary 4AP linker. Pre-clinical data have shown that this optimization of payload placement and linker composition, combined with the stability afforded by HIPS chemistry, leads to better tolerability and expanded therapeutic index. TRPH-222 is currently in IND enabling GLP studies.
About Triphase Accelerator
Triphase Accelerator is a private drug development company with a primary focus on oncology and with operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS. It has a strategic relationship with Celgene for oncology-focused drug development opportunities. For more information, visit www.triphaseco.com or LinkedIn.
About SMARTag® Technology
Catalent’s proprietary SMARTag platform, which provides site-specific protein-modification and linker technologies, was developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The aldehyde tag technology employs natural co-translational modifications found in human cells to create one or more attachment sites at designated positions on protein molecules. These chemical “handles’’ are then stably conjugated to payloads (e.g. cytotoxic or effector) to prevent their systemic release. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation, and defined stoichiometry of drug–protein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. Catalent acquired Redwood Bioscience in 2014.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,400 scientists, at more than 30 facilities across 5 continents and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com
More products. Better treatments. Reliably supplied.™